Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA; email:
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA.
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:555-575. doi: 10.1146/annurev-pharmtox-010818-021856. Epub 2018 Sep 26.
The transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.
转录因子红系 2 相关因子 2(NRF2)是氧化还原、代谢和蛋白质稳态的中央调节剂,与许多其他信号级联相交。尽管对 NRF2 信号的复杂性质的理解不断加深,但只有一种针对 NRF2 的治疗方法,即二甲基富马酸,用于治疗多发性硬化症。新疗法的发现受到 NRF2 水平因生理和病理情况而异的事实所困扰。因此,正确的时机和靶向 NRF2 途径的操作对于制定有效的治疗方案至关重要。在这篇综述中,我们总结了 NRF2 的调节和下游靶标。此外,我们还讨论了 NRF2 在癌症、神经退行性疾病和糖尿病以及心血管、肾脏和肝脏疾病中的作用,特别强调了基于 NRF2 的治疗方法,包括已进入临床试验的治疗方法。